Clinical Trial: Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease

U.S., Oct. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07872423) titled 'Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease' on March 19.

Brief Summary: This study adopted a multicenter, randomized, double-blind, placebo-controlled approach with the best supportive treatment design, using recombinant humanized anti-interleukin-6 receptor monoclonal antibody injection (VDJ001) to treat idiopathic multicenter Castleman disease (iMCD).

Study Start Date: Jan. 27, 2025

Study Type: INTERVENTIONAL

Condition: Anti IL-6R Castleman's Disease, Multicentric

Intervention: DRUG: Recombinant Humanized Anti-Interleukin-6 Receptor Monoclonal Antibody Injection

VDJ001 is a recombin...